Authorized purpose: NeuroQuant automatically labels, visualizes, and volumetrically quantifies segmentable brain structures and lesions from MR images, optionally using T2 FLAIR and T2* GRE/SWI for lesion analysis; outputs require radiologist/neuroradiologist review and may be compared with reference percentiles.
Clinical role
Segmentation, volumetric quantification, and longitudinal comparison support
Images and patients
MRI · Brain
Key limitation
Keep in mind: Clinical output requires radiologist/neuroradiologist review; the device is prescription-only; specified acquisition protocols are recommended; and the output is not a substitute for full clinical interpretation.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: NeuroQuant automatically labels, visualizes, and volumetrically quantifies segmentable brain structures and lesions from MR images, optionally using T2 FLAIR and T2* GRE/SWI for lesion analysis; outputs require radiologist/neuroradiologist review and may be compared with reference percentiles.
Which images or clinical context are in scope?Modality: MRI Anatomy or clinical context: Brain Input: 3D T1-weighted MR images; optional T2 FLAIR and T2* GRE/SWI series; DICOM Storage input from an MRI scanner or PACS; specified protocols are recommended.
Who uses it?Intended users: Medical professionals; clinical outputs must be reviewed by a radiologist or neuroradiologist and may be forwarded to the referring neurologist.
What does the software produce?Output: Numerical brain and lesion volumes, grayscale intensity maps, color overlays, segmented image series, and morphometric reports in standard DICOM for display on commercial DICOM workstations/PACS; age/gender-matched normative percentiles and change analysis may be provided.
What is its most important limitation?Key limitation: Clinical output requires radiologist/neuroradiologist review; the device is prescription-only; specified acquisition protocols are recommended; and the output is not a substitute for full clinical interpretation.
Clinical takeaway. Clinical role: NeuroQuant automatically labels, visualizes, and volumetrically quantifies segmentable brain structures and lesions from MR images, optionally using T2 FLAIR and T2* GRE/SWI for lesion analysis; outputs require radiologist/neuroradiologist review and may be compared with reference percentiles.
Evidence takeaway. Evidence from the reviewed source record: FDA performance testing covered brain segmentation, FLAIR lesion segmentation, and MCH detection models; FLAIR mean Dice 0.70 (SD 0.14) and MCH median F1 0.60 were reported, with separate test sets from training.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
NeuroQuant automatically labels, visualizes, and volumetrically quantifies segmentable brain structures and lesions from MR images, optionally using T2 FLAIR and T2* GRE/SWI for lesion analysis; outputs require radiologist/neuroradiologist review and may be compared with reference percentiles.
3D T1-weighted MR images; optional T2 FLAIR and T2* GRE/SWI series; DICOM Storage input from an MRI scanner or PACS; specified protocols are recommended.
Numerical brain and lesion volumes, grayscale intensity maps, color overlays, segmented image series, and morphometric reports in standard DICOM for display on commercial DICOM workstations/PACS; age/gender-matched normative percentiles and change analysis may be provided.
Clinical output requires radiologist/neuroradiologist review; the device is prescription-only; specified acquisition protocols are recommended; and the output is not a substitute for full clinical interpretation.
FDA performance testing covered brain segmentation, FLAIR lesion segmentation, and MCH detection models; FLAIR mean Dice 0.70 (SD 0.14) and MCH median F1 0.60 were reported, with separate test sets from training.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
FDA performance testing covered brain segmentation, FLAIR lesion segmentation, and MCH detection models; FLAIR mean Dice 0.70 (SD 0.14) and MCH median F1 0.60 were reported, with separate test sets from training.
NeuroQuant model validation across brain, FLAIR, and MCH pipelines
DesignRetrospective model validation with separate training and test datasets
PopulationBrain segmentation: 1,473 training 3D T1 series from more than 16 institutions and 30-patient test set; FLAIR: 340 training series from 22 institutions and 63-patient test set; MCH: 463 training 2D T2*GRE/SWI series from more than 68 institutions and 117-patient test set.
Scopeexact submission
Tested versionNeuroQuant submitted in K241098; build not stated
IndependenceIndependence not established
K241098
The FDA establishes separation of training and test data, not independent investigators or sponsorship. The reported FLAIR and MCH values are model-specific and should not be generalized to every NeuroQuant output.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
Not established in reviewed sources
Reviewed sources checked
Exact FDA submission
Checked 2026-09-04
No native submission-identifier match was found in the checked openFDA radiology recall snapshot. Product-name, manufacturer, and adverse-event searches remain necessary; this does not establish that no recall or safety report exists.
Pricing & contractsPublic price, contract terms, and reimbursement
Aetna Clinical Policy Bulletin 0739 classifies automated quantification of brain MRI as experimental, investigational, or unproven and lists Category III CPT codes 0865T and 0866T as not covered for the indications in the bulletin. This is service-level Aetna policy, not an exact NeuroQuant eligibility or universal coverage determination.
Not covered for indications listed in Aetna CPB 0739; automated quantification of brain MRI is classified as experimental, investigational, or unproven
Aetna · United States; plan and benefit terms vary
Policy last reviewed 2026-07-24. This service-level policy does not prove eligibility for a particular NeuroQuant version, member, indication, site, or claim.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: 3D T1-weighted MR images; optional T2 FLAIR and T2* GRE/SWI series; DICOM Storage input from an MRI scanner or PACS; specified protocols are recommended.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: DICOM Storage receives MR series from an MRI scanner or PACS and returns DICOM image series and reports to DICOM workstations/PACS; transient data storage only is described.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: On-premise computing appliance
Scope: Exact FDA submission. The exact FDA submission describes the device as a computing appliance; current hosting region and commercial deployment options were not inferred.
Confirm processing location, queue ownership, exclusions and exact AI build.
Source context, not route validation: Numerical brain and lesion volumes, grayscale intensity maps, color overlays, segmented image series, and morphometric reports in standard DICOM for display on commercial DICOM workstations/PACS; age/gender-matched normative percentiles and change analysis may be provided.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Numerical brain and lesion volumes, grayscale intensity maps, color overlays, segmented image series, and morphometric reports in standard DICOM for display on commercial DICOM workstations/PACS; age/gender-matched normative percentiles and change analysis may be provided.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
DICOM Storage receives MR series from an MRI scanner or PACS and returns DICOM image series and reports to DICOM workstations/PACS; transient data storage only is described.
The exact submission describes DICOM Storage receipt from an MRI scanner or PACS and standard DICOM image-series/report output for commercial DICOM workstations.
The official NeuroQuant Installed Quick Start Guide describes 3D T1 DICOM input, AETitle/report selection, automated processing, and output to a configured PACS; the guide is a v3.0 family manual and is not treated as proof of the exact K241098 build.
product family · checked 2026-09-07
Family manual context; current exact-version compatibility requires confirmation.
CorTechs' current NeuroQuant page describes cloud-based brain segmentation, quantification, comparison, and adaptable reports that integrate with radiology workflows; this current family description is not used to override the exact FDA appliance deployment.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Human reviewedStatus
2026-09-07Last searched
24Fields reviewed
12Source classes checked
20Screened PubMed leads
5Screened trial leads
0Unreviewed FDA recall leads
The stored PubMed, ClinicalTrials.gov, and exact-submission recall metadata candidates were screened by identifier and count. The records were not treated as a full paper, trial, or postmarket review. The current discovery snapshot contains 20 PubMed and 5 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, vendor product page, vendor manual, payer policy, literature index, trial registry, fda device recall, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not verified - checked 2026-09-07 - Exact FDA submission
No public amount, range, currency, geography, or contract term was established.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Security: Not verified - checked 2026-09-07 - Exact FDA submission
The reviewed sources do not establish a scoped security audit, certification, or control set.
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-09-07 - Exact FDA submission
Training, credentialing, and implementation support terms were not established.
Monitoring: Not verified - checked 2026-09-07 - Exact FDA submission
Current post-deployment monitoring and change-control practices were not established.
Authorized purpose: ANDI 2.2 processes brain MR images for atlas-assisted visualization, segmentation and volumetric quantification, presenting adjunctive DICOM-readable information for trained medical professionals; it does not predict, diagnose or interpret brain health.
Authorized purpose: Morph automatically labels, visualizes, and volumetrically quantifies segmentable brain structures from MR images and may compare measurements with reference percentile data; it is adjunctive and not the sole basis for final decisions.
Authorized purpose: Brain MRI morphometry and white matter hyperintensity quantification, including normative comparison and longitudinal change assessment for clinician review.
Authorized purpose: Adjunctive quantitative brain MRI analysis that compares patient measures with normative and longitudinal references; a physician reviews all results and makes the clinical decision.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.